Rønnow, Sarah Rank
Sand, Jannie Marie Bülow
Staunstrup, Line Mærsk
Bahmer, Thomas
Wegmann, Michael
Lunding, Lars
Burgess, Janette
Rabe, Klaus
Sorensen, Grith Lykke
Fuchs, Oliver
Mutius, Erika V.
Hansen, Gesine
Kopp, Matthias Volkmar
Karsdal, Morten
Leeming, Diana Julie
Weckmann, Markus
,
Funding for this research was provided by:
Danish Agency for Science and Higher Education (Danish Agency for Science and Higher Education)
Article History
Received: 4 January 2022
Accepted: 28 March 2022
First Online: 13 April 2022
Declarations
:
: (ALLIANCE, NCT02419274). The study was approved by the Copenhagen County Scientific Ethics Committee (jr: KA 99070 gm), and written informed consent was obtained from all participants.
: All authors agreed and approved the submission of this manuscript.
: SRR, JMBS, and DJL are employees and stockholders of Nordic Bioscience A/S; LMS, TB, MW, LL, JB, GLS, and MW declares no conflict of interest; KR declares no conflict of interest, he received grants from Boehringer Ingelheim and personal fees from Antra Zenaca, Novartis, Sanofi, Regeneron, Roche, Chiesi pharmaceuticals outside the submitted work; OF declares no conflict of interest with this publication, he is a consultant for Menarini and Vifor, has received speaker’s fees from Vertex aha! Allergy Centre Switzerland, Menarini, Novartis, ALK and has received travel support from Milupa/Nutricia, Stallergnes Greer and Bencard; EVM declares personal fees from GlaxoSmithKline & Co. KG, Decision Resources Inc., London, Pick Research Solutions, Novartis Pharma GmbH, ALK Scherax Arzneimittel GmbH, Sandler Program for Asthma Research (SPAR), Aptel Research, and Penn Technology Partnership, grants from Airsonett AB, personal fees from American Academy of Allergy Asthma & Immunology, grants from European Commission, grants from German Research Foundation, personal fees from Massachusetts Medical Society, outside the submitted work; In addition, EVM has a patent Publication number EP2361632: with royalties paid to Protectimmun GmbH, a patent Publication number EP 1411977: licensed to Protectimmun GmbH, a patent Publication number EP1637147: licensed to Protectimmun GmbH, and a patent Publication number EP 1964570: licensed to Protectimmun GmbH; GH declares no conflict of interest and is a consultant for Novartis and Sanofi; MVK declares personal fees from Novartis Pharma GmbH, Allergopharma GmbH, ALK Abello, Chiesi GmbH, Infectopharm GmbH, Meda GmbH, and Abbvie GmbH, outside the submitted work; MK is a fulltime employee and stockholder of Nordic Bioscience A/S.